Key result
An IPV booster in previously OPV-immunized children marginally enhanced humoral immunity but failed to offer intestinal immunity against poliovirus.
Why the study?
The study compared mucosal and humoral responses to poliovirus vaccines administered to previously OPV-immunized children to assess the immunity gap in areas of high poliovirus transmission.
Does IPV boost intestinal and humoral immunity in previously OPV-immunized children under five years of age?
RCT
Cluster-randomized
Yes
Does IPV boost intestinal and humoral immunity in previously OPV-immunized children under five years of age?
Providing an IPV booster to previously OPV-immunized children marginally enhances humoral immunity but fails to offer intestinal immunity.
Limits the utility of IPV boosters for interrupting viral transmission in endemic regions; challenges eradication strategies.
The oral poliovirus vaccine (OPV) has been the mainstay of polio eradication, especially in low-income countries, and its use has eliminated wild poliovirus type 2. However, the inactivated poliovirus vaccine (IPV) is safer than OPV, as IPV protects against paralytic poliomyelitis without producing adverse reactions. The present study compared mucosal and humoral responses to poliovirus vaccines administered to previously OPV-immunized children to assess the immunity gap in children in areas of high poliovirus transmission. A cluster-randomized trial was implemented in three high-risk districts of Pakistan-Karachi, Kashmore, and Bajaur-from June 2013 to May 2014. This trial was community-oriented and included three arms, focusing on healthy children below five years of age. The study involved the randomization of 387 clusters, of which 360 were included in the final analysis. The control arm (A) received the routine polio program bivalent poliovirus vaccine (bOPV). The second arm (B) received additional interventions, including health camps providing routine vaccinations and preventive maternal and child health services. In addition to the interventions in arm B, the third arm (C) was also provided with IPV. Blood and stool samples were gathered from children to evaluate humoral and intestinal immunity. The highest levels of poliovirus type 1 serum antibodies were observed in Group C (IPV + OPV). The titers for poliovirus type 2 (P2) and poliovirus type 3 (P3) were noticeably higher in those who had received a routine OPV dose than in those who had not across all study groups and visits. Providing an IPV booster after at least two OPV doses could potentially fill immunity gaps in regions where OPV does not show high efficacy. However, IPV only marginally enhances humoral immunity and fails to offer intestinal immunity, which is critical to stop the infection and spread of live poliovirus in populations that have not been exposed before.
No takes yet. Share an insight, caveat, or question.
Habib et al. (2023) conducted an RCT in Healthy children. Inactivated poliovirus vaccine (IPV) booster vs. Routine bivalent poliovirus vaccine (bOPV) with or without additional health camp interventions was evaluated on Mucosal and humoral responses (poliovirus serum antibodies and intestinal immunity). An IPV booster in previously OPV-immunized children marginally enhanced humoral immunity but failed to offer intestinal immunity against poliovirus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: